These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 28219749)

  • 1. Behavioral phenotypes associated with MPTP induction of partial lesions in common marmosets (Callithrix jacchus).
    Phillips KA; Ross CN; Spross J; Cheng CJ; Izquierdo A; Biju KC; Chen C; Li S; Tardif SD
    Behav Brain Res; 2017 May; 325(Pt A):51-62. PubMed ID: 28219749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level.
    Kupsch A; Sautter J; Schwarz J; Riederer P; Gerlach M; Oertel WH
    Brain Res; 1996 Nov; 741(1-2):185-96. PubMed ID: 9001722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. L-DOPA-induced behavioral sensitization of motor activity in the MPTP-treated common marmoset as a Parkinson's disease model.
    Ando K; Inoue T; Itoh T
    Pharmacol Biochem Behav; 2014 Dec; 127():62-9. PubMed ID: 25449794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progression and recovery of Parkinsonism in a chronic progressive MPTP-induction model in the marmoset without persistent molecular and cellular damage.
    Franke SK; van Kesteren RE; Wubben JA; Hofman S; Paliukhovich I; van der Schors RC; van Nierop P; Smit AB; Philippens IH
    Neuroscience; 2016 Jan; 312():247-59. PubMed ID: 26431624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. REM sleep behavior disorder in the marmoset MPTP model of early Parkinson disease.
    Verhave PS; Jongsma MJ; Van den Berg RM; Vis JC; Vanwersch RA; Smit AB; Van Someren EJ; Philippens IH
    Sleep; 2011 Aug; 34(8):1119-25. PubMed ID: 21804674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to monkeys: behavioural, morphological and biochemical correlates.
    Albanese A; Granata R; Gregori B; Piccardi MP; Colosimo C; Tonali P
    Neuroscience; 1993 Aug; 55(3):823-32. PubMed ID: 8105418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A modified MPTP treatment regime produces reproducible partial nigrostriatal lesions in common marmosets.
    Iravani MM; Syed E; Jackson MJ; Johnston LC; Smith LA; Jenner P
    Eur J Neurosci; 2005 Feb; 21(4):841-54. PubMed ID: 15787691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurobehavioral protection by single dose l-deprenyl against MPTP-induced parkinsonism in common marmosets.
    Ando K; Maeda J; Inaji M; Okauchi T; Obayashi S; Higuchi M; Suhara T; Tanioka Y
    Psychopharmacology (Berl); 2008 Jan; 195(4):509-16. PubMed ID: 17879087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.
    Kupsch A; Sautter J; Götz ME; Breithaupt W; Schwarz J; Youdim MB; Riederer P; Gerlach M; Oertel WH
    J Neural Transm (Vienna); 2001; 108(8-9):985-1009. PubMed ID: 11716151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic MPTP administration regimen in monkeys: a model of dopaminergic and non-dopaminergic cell loss in Parkinson's disease.
    Masilamoni GJ; Smith Y
    J Neural Transm (Vienna); 2018 Mar; 125(3):337-363. PubMed ID: 28861737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroprotective effects of riluzole in early phase Parkinson's disease on clinically relevant parameters in the marmoset MPTP model.
    Verhave PS; Jongsma MJ; Van Den Berg RM; Vanwersch RA; Smit AB; Philippens IH
    Neuropharmacology; 2012 Mar; 62(4):1700-7. PubMed ID: 22178201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methylene Blue Ameliorates Olfactory Dysfunction and Motor Deficits in a Chronic MPTP/Probenecid Mouse Model of Parkinson's Disease.
    Biju KC; Evans RC; Shrestha K; Carlisle DCB; Gelfond J; Clark RA
    Neuroscience; 2018 Jun; 380():111-122. PubMed ID: 29684508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nitric oxide synthase inhibition and MPTP-induced toxicity in the common marmoset.
    Mackenzie GM; Jackson MJ; Jenner P; Marsden CD
    Synapse; 1997 Jul; 26(3):301-16. PubMed ID: 9183819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Individual and Familial Susceptibility to MPTP in a Common Marmoset Model for Parkinson's Disease.
    Franke SK; van Kesteren RE; Hofman S; Wubben JA; Smit AB; Philippens IH
    Neurodegener Dis; 2016; 16(5-6):293-303. PubMed ID: 26999593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Succinobucol, a Non-Statin Hypocholesterolemic Drug, Prevents Premotor Symptoms and Nigrostriatal Neurodegeneration in an Experimental Model of Parkinson's Disease.
    Santos DB; Colle D; Moreira EL; Hort MA; Godoi M; Le Douaron G; Braga AL; Assreuy J; Michel PP; Prediger RD; Raisman-Vozari R; Farina M
    Mol Neurobiol; 2017 Mar; 54(2):1513-1530. PubMed ID: 26852411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Magnetic resonance imaging and tensor-based morphometry in the MPTP non-human primate model of Parkinson's disease.
    Modo M; Crum WR; Gerwig M; Vernon AC; Patel P; Jackson MJ; Rose S; Jenner P; Iravani MM
    PLoS One; 2017; 12(7):e0180733. PubMed ID: 28738061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new model to study compensatory mechanisms in MPTP-treated monkeys exhibiting recovery.
    Mounayar S; Boulet S; Tandé D; Jan C; Pessiglione M; Hirsch EC; Féger J; Savasta M; François C; Tremblay L
    Brain; 2007 Nov; 130(Pt 11):2898-914. PubMed ID: 17855373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trazodone alleviates both dyskinesia and psychosis in the parkinsonian marmoset model of Parkinson's disease.
    Hamadjida A; Nuara SG; Gourdon JC; Huot P
    J Neural Transm (Vienna); 2018 Sep; 125(9):1355-1360. PubMed ID: 29247391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two new test methods to quantify motor deficits in a marmoset model for Parkinson's disease.
    Verhave PS; Vanwersch RA; van Helden HP; Smit AB; Philippens IH
    Behav Brain Res; 2009 Jun; 200(1):214-9. PubMed ID: 19378465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intervention with 7,8-dihydroxyflavone blocks further striatal terminal loss and restores motor deficits in a progressive mouse model of Parkinson's disease.
    Sconce MD; Churchill MJ; Moore C; Meshul CK
    Neuroscience; 2015 Apr; 290():454-71. PubMed ID: 25655214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.